Primo N. Lara, Jr., MD, explains how a newly diagnosed advanced renal cell carcinoma (RCC) patient should be treated in the 2nd line following I-O failure at the 2018 Annual Meeting.
The treatment path following I-O failure
Primo N. Lara, Jr., MD, explains how a newly diagnosed advanced renal cell carcinoma (RCC) patient should be treated in the 2nd line following I-O failure at the 2018 Annual Meeting.